Pear Bio

Summary

Seedtable Score

65

Locations

• London

Company Size

• 11 - 51

Last Stage Round

• Series A

Industry

• Biotech
• Health Tech
• Pharma

Insights

Pear Bio, based in London, is disrupting healthcare with its cancer treatment predictor software. Operating on a B2B model, Pear Bio aims to enhance oncologists' decision-making through advanced predictive analytics. Unlike traditional methods reliant on clinical trials and historical data, Pear Bio’s software directly predicts effective cancer treatments, potentially reducing less effective treatments and patient suffering. Supported by investors like Hoxton Ventures and Octopus Ventures, Pear Bio is poised to innovate in the biotech and health tech sectors.

• Series A (2023) $14.0M

---

• Unknown (2020-01-01)

---

• Seed (2020-01-01) $1.2M

---

Investors

• Hoxton Ventures Series A

---

• Octopus Ventures Series A

---

• Octopus Ventures Series A

---

• Fly Ventures Series A

---

Full Company Profile

Access details of the company management, and other intelligence on this company by registering for Seedtable

---